Literature DB >> 182016

Fast neutron beam radiotherapy of glioblastoma multiforme.

R G Parker, H C Berry, A J Gerdes, M D Soronen, C M Shaw.   

Abstract

Twenty-one patients with glioblastoma multiforme were treated with fast neutron beam irradiation of the whole brain. Therapy was well tolerated up to calculated doses of 1.850 radn+y in 12-18 increments over 6 weeks. The survival rate 6 month after initiation of treatment was 62%, not significantly different from conventional photon therapy; average posttreatment survival appears to be shortened compared to photon therapy. No improvement or prolonged maintenance of existing neurologic function was observed. Autopsy findings in seven patients showed replacement of tumor by coagulative necrosis persisting at least 16 months posttreatment, paucity of tumor cells with infrequent mitosis, and suppression of macrophage response. These findings differ from those in conventionally irradiated patients. No treatment-related changes were documented by conventional gross and histologic studies of the irradiated brains distant from the tumors. Thus the deaths of patients in this study appear to be related to unexplained causes other than progressive growth of tumor.

Entities:  

Mesh:

Year:  1976        PMID: 182016     DOI: 10.2214/ajr.127.2.331

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  CT and MR for brain tumor implant therapy using CF-252 neutrons.

Authors:  Y Maruyama; H W Chin; A B Young; J Beach; P Tibbs; S Goldstein; W Markesbery
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

Review 3.  Fast neutron therapy for malignant astrocytomas. A review.

Authors:  P D Kurup; T F Pajak; J S Nelson; J Mansell; F R Hendrickson; L Cohen; T W Griffin
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.